{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"The percent of patients who were shown as having a partial remission or better based on definitions of response in RECIST 1.1. At least a 30% decrease in the sum of the diameters of target lesions, in reference to baseline sum diameters, needs to be confirmed to be considered as partial response or better. Note: There were no patients with a partial or complete response.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive palifosfamide IV over 30 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Palifosfamide)"}],"paramType":"NUMBER","populationDescription":"All patients who enrolled and received treatment with at least one post baseline assessment.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Overall Response Rate (Defined as Partial Response or Complete Response)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}